MIC current news
The updated ‘National Malaria Treatment Guidelines 2017’ (final draft version) can be accessed on the NICD website (www.nicd.ac.za).
Ning and colleagues recently published their research in the Journal of Psychopharmacology. Their study looked at reducing the dose of olanzapine or risperidone in stable schizophrenic patients and the effect on cognitive function and symptoms.
We need your help, please. We are conducting a research study to understand healthcare worker knowledge of parts of the new ART guidelines. The survey data will be collected anonymously.
There is an optional prize draw after completion (details stored separately from survey answers, to protect anonymity). To participate, click here.
Philip Joseph and colleagues have published their meta-analysis of studies which looked at fixed-dose combinations of antihypertensives plus statins with or without aspirin.
An interesting observational study analysis was recently published in Nature Medicine, reporting that initial predictions of the effect of the pandemic on Africa were inaccurate.
We are pleased to announce that our App – now available on both Android and iPhone – has had a useful new tool added: a paediatric ARV dosing tool.
We’ve got condoms and PrEP, but with huge focus being placed on preventing HIV transmission, what’s in the pipeline to bolster our HIV prevention armamentarium?
We have been inundated with questions about the COVID-19 vaccine and vaccination programme as, we are sure, have you. The National Department of Health has brought out a useful, patient-friendly booklet.
A retrospective longitudinal pharmacovigilance study highlights the importance of pharmaceutical supervision at admission.
Solomon and colleagues performed a retrospective cohort study on a subsection of women in the SWAN longitudinal study. Their interest was the long-term effect of sleep medications on sleep disturbances.
A medicine safety letter highlights the risk of acute kidney injury in patients treated with fluoroquinolones concomitantly with ace-inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).